Phase 1b study results of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy

David A. Smith,Paul Conkling,Donald A. Richards, Maria Regina C. Flores,John J. Nemunaitis,Thomas E. Boyd,Alain C. Mita,Guillaume de La Bourdonnaye,David Wages,Alice S. Bexon

Lung Cancer（2012）

引用 2|浏览11

暂无评分

摘要

Background: IMO-2055 is a novel TLR-9 agonist potentially enhancing efficacy of targeted therapies through immune stimulation. Xenograft data show anti-tumor synergy with E and bev.

查看译文

关键词

novel tlr9 agonist,bevacizumab,lung cancer,chemotherapy,non-small

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要